Departure Of Ceo (new) — Current principal executive officer will step down upon stockholder approval, though he remains with the company as General Counsel.
Departure Of Cfo (new) — Current principal financial officer will be replaced upon stockholder approval of the control-change proposals.

NASDAQ: SNSE Sensei Biotherapeutics, Inc. 8-K

Sensei Biotherapeutics plans board overhaul and C-suite changes tied to control shift

Filed April 16, 2026 · Period ending April 10, 2026 · ~1 min read

4 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SNSE commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 3, 2026 3:09 AM